SK chemicals Site Manager● SK Chemical Cheongju Plant expanded solid formulation
production facility
SK Chemical (CEO and Vice-chairman Kim Chang Geun) announced to have a groundbreaking ceremony of Cheongju plant to expand soli formulation production facility on the 24th.
The expansion of Cheongju plant will be progressed by two stages (1st: March 2011 ~ June 2012 / 2nd: October 2012 ~ December 2013) with 50 billion won investment.
SK Chemical determined the expansion due to the shortage of production capacity for sales increase, audit increase by overseas institutions and production expansion by R&D increase though Cheongju, Ansan (solid formulation and patch) and Osan (vaccine and blood components).
This expansion enables SK Chemical to satisfy overseas institution’s audit standard with over 10 times per year and also secure [global GMP] satisfying CGMP and EU GMP standard. The production and management efficiency is also expected by the successful integration of Ansan Plant.
CEO Lee In Seok of SK Chemical Life Science Biz remarked that “the first expansion may increase the annual production to 2 billion tablets which is triple to the current, and a patch line with Trast will be included in the 2nd expansion.”
SK Chemical Cheongju Plant will play a vital role in providing Mvix, the impotency drug, patch arthritis Trast, Ginexin, improvement of blood circulation, No.1 natural new medicine Joins and Casca hypertension medicine excluding vaccines and blood components.
SK Chemical plans to lead to develop domestic life science level with equipping [global GMP] standard capacity in addition to R&D experience in developing 3 new drugs.